Skip Navigation
Skip to contents

Intest Res : Intestinal Research

Search
Advanced Search
IMPACT FACTOR
mobile search button mobile menu button

Search

Page Path
HOME > Search
2 "Dong-Il Park"
Filter
Filter
Article category
Publication year
Review
Inflammatory bowel diseases
Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases
Soo-Kyung Park, Chang Hwan Choi, Jaeyoung Chun, Heeyoung Lee, Eun Sun Kim, Jae Jun Park, Chan Hyuk Park, Bo-In Lee, Yunho Jung, Dong-Il Park, Do Young Kim, Hana Park, Yoon Tae Jeen, IBD Research Group of the Korean Association for the Study of Intestinal Diseases
Intest Res 2020;18(1):18-33.   Published online January 30, 2020
DOI: https://doi.org/10.5217/ir.2019.09155
AbstractAbstract PDFPubReaderePub
The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viral hepatitis is determined by the interaction between the virus and the host’s immunity, and the risk of reactivation increases if immunity is compromised by immunosuppression therapy. Parts of Asia, including Korea, still show intermediate endemicity for the hepatitis A virus and hepatitis B virus compared with the United States and Western Europe. Thus, members of IBD research group of the Korean Association for the Study of Intestinal Diseases have produced a guideline on the prevention and management of viral hepatitis in IBD.

Citations

Citations to this article as recorded by  
  • Prevalence of viral hepatitis A and C in patients with inflammatory bowel disease: a nationwide population-based study in South Korea
    Jin Hwa Park, Sang Hyoung Park, Sang Pyo Lee, Kang Nyeong Lee, Hang Lak Lee, Oh Young Lee, Soorack Ryu, Junwon Go
    The Korean Journal of Internal Medicine.2026; 41(1): 95.     CrossRef
  • Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the Phase 3 GRAVITI study
    Wenjia Liu, Hong Guo, Tae Oh Kim, Ken Takeuchi, Tadakazu Hisamatsu, Jennifer Fable, Mobolaji Olurinde, Bryan Wahking, Keira Herr, Jianmin Zhuo, Qian Cao
    Intestinal Research.2026;[Epub]     CrossRef
  • ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
    Henit Yanai, Pierre Ellul, Bram Verstockt, Thomas Greuter, Uri Kopylov, María José Casanova, Gabriele Dragoni, Piotr Eder, Maria Manuela Estevinho, Candida Abreu, Federica Furfaro, Christina Kapizioni, Konstantinos Karmiris, Konstantinos Katsanos, Julien
    Journal of Crohn's and Colitis.2026;[Epub]     CrossRef
  • Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases
    Niloofar Khoshnam-Rad, Homayoon Vahedi, Anahita Sadeghi, Mansoor Rastegarpanah, Soha Namazi, Amir Anushiravani, Ali Reza Sima, Shabnam Shahrokh, Sudabeh Alatab, Reza Malekzadeh
    Middle East Journal of Digestive Diseases.2023; 15(2): 83.     CrossRef
  • Protective role of flavonoids quercetin and silymarin in the viral-associated inflammatory bowel disease: an updated review
    Elham Zarenezhad, Hussein T. Abdulabbas, Ahmed Shayaa Kareem, Seyed Amin Kouhpayeh, Silvia Barbaresi, Sohrab Najafipour, Abdulbaset Mazarzaei, Mitra Sotoudeh, Abdolmajid Ghasemian
    Archives of Microbiology.2023;[Epub]     CrossRef
  • The impact of medication belief on adherence to infliximab in patients with Crohn’s disease
    Shuyan Li, Yan Ma, Hongling Sun, Zijun Ni, Shurong Hu, Yan Chen, Meijuan Lan
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID
    Yoo Jin Lee, Seong-Eun Kim, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seung-Jae Myung
    Intestinal Research.2022; 20(2): 171.     CrossRef
  • Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease
    Ji Min Lee, Shu-Chen Wei, Kang-Moon Lee, Byong Duk Ye, Ren Mao, Hyun-Soo Kim, Soo Jung Park, Sang Hyoung Park, Eun Hye Oh, Jong Pil Im, Byung Ik Jang, Dae Bum Kim, Ken Takeuchi
    Gut and Liver.2022; 16(3): 396.     CrossRef
  • Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease
    Eun Ae Kang, Jae Hee Cheon
    Gut and Liver.2022; 16(4): 501.     CrossRef
  • Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment
    Soo Min Ahn, Jonggi Choi, Byong Duk Ye, Suk-Kyun Yang, Ji Seon Oh, Yong‑Gil Kim, Chang-Keun Lee, Bin Yoo, Sang Hyoung Park, Seokchan Hong
    Gut and Liver.2022; 16(4): 567.     CrossRef
  • Inflammatory bowel disease in Korea: epidemiology and pathophysiology
    Jung Won Lee, Chang Soo Eun
    The Korean Journal of Internal Medicine.2022; 37(5): 885.     CrossRef
  • Viral Hepatitis in Patients with Inflammatory Bowel Disease
    Seung Hwan Shin, Sang Hyoung Park
    The Korean Journal of Gastroenterology.2022; 80(2): 51.     CrossRef
  • Vaccination strategies for Korean patients with inflammatory bowel disease
    Yoo Jin Lee, Eun Soo Kim
    The Korean Journal of Internal Medicine.2022; 37(5): 920.     CrossRef
  • Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study
    Hong Yang, Zhihua Ran, Meng Jin, Jia-Ming Qian
    Gut and Liver.2022; 16(5): 726.     CrossRef
  • Do We Have an Opportunity to Avoid Opportunistic Infections in Asian Patients with Inflammatory Bowel Disease?
    Suhyun Park, Sang Hyoung Park
    Gut and Liver.2022; 16(5): 663.     CrossRef
  • Natural history of inflammatory bowel disease: a comparison between the East and the West
    Eun Mi Song, Suk-Kyun Yang
    Intestinal Research.2022; 20(4): 418.     CrossRef
  • Hepatobiliary Impairments in Patients with Inflammatory Bowel Diseases: The Current Approach
    Vlad Alexandru Ionescu, Gina Gheorghe, Valentin Nicolae Varlas, Ana Maria Alexandra Stanescu, Camelia Cristina Diaconu
    Gastroenterology Insights.2022; 14(1): 13.     CrossRef
  • Viral infections in inflammatory bowel disease: Tips and tricks for correct management
    Vincenzo Craviotto, Federica Furfaro, Laura Loy, Alessandra Zilli, Laurent Peyrin-Biroulet, Gionata Fiorino, Silvio Danese, Mariangela Allocca
    World Journal of Gastroenterology.2021; 27(27): 4276.     CrossRef
  • SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID
    Yoo Jin Lee, Seong-Eun Kim, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seung-Jae Myung
    The Korean Journal of Gastroenterology.2021; 78(2): 117.     CrossRef
  • Current status of inflammatory bowel diseases in Korea
    Suk-Kyun Yang
    Journal of the Korean Medical Association.2021; 64(9): 572.     CrossRef
  • A clinical case of ulcerative colitis in a patient with viral hepatitis
    E. D. Kosmachova, M. S. Iakovenko, K. A. Yumukian
    South Russian Journal of Therapeutic Practice.2020; 1(3): 95.     CrossRef
  • 12,964 View
  • 303 Download
  • 19 Web of Science
  • 21 Crossref
Close layer
Original Article
Inflammatory bowel diseases
Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study
Soo-Kyung Park, Sang Hyun Park, Chang Soo Eun, Geom Seog Seo, Jong Pil Im, Tae Oh Kim, Dong-Il Park
Intest Res 2019;17(3):349-356.   Published online February 8, 2019
DOI: https://doi.org/10.5217/ir.2018.00064
AbstractAbstract PDFPubReaderePub
Background/Aims
A once-daily (OD) regimen of 5-aminosalicylic acid (5-ASA) was easier to comply with than a divided daily (DD) regimen, and that treatment efficacy for ulcerative colitis (UC) was not affected by the dosing regimen. This study evaluated treatment adherence of OD and DD dosing in the Korean UC patients.
Methods
This study was a prospective, multicenter, randomized trial. UC patients were enrolled who have been in remission for more than 3 months. Patients were randomly assigned to the OD or DD group in a 1:1 ratio. The primary endpoint was adherence rate measured by tablet counts and self-reported adherence rate at 3, 6, 9, and 12 months. The relapse rate was measured at 1 year.
Results
Data from the 180 patients who were randomized were analyzed. Both self-reported adherence rate and adherence rate measured by tablet counts were not different at every points, including 1 year. The patients’ satisfaction of the OD group was higher than that of the DD group (P<0.001). At 1 year, 91.2% and 95.5% of patients in the OD group and DD group had maintained clinical remission, respectively (P=0.37).
Conclusions
The adherence rates were not different between the OD group and DD group. The patients’ satisfaction was higher in the OD group than in the DD group. 5-ASA OD dosing might have the same effect as DD for the maintenance of UC remission.

Citations

Citations to this article as recorded by  
  • Non-Adherence Rate to Oral Mesalamine in Ulcerative Colitis Patients: A Systematic Review with Meta-Analysis
    Cristiano Pagnini, Elisabetta Antonelli, Barbara Scrivo, Maria Cappello, Marco Soncini, Roberto Vassallo, Giammarco Mocci, Maria Carla Di Paolo
    Journal of Personalized Medicine.2025; 15(4): 123.     CrossRef
  • British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025
    Gordon W Moran, Morris Gordon, Vassiliki Sinopoulou, Shellie J Radford, Ana-Maria Darie, Sudheer Kumar Vuyyuru, Laith Alrubaiy, Naila Arebi, Jonathan Blackwell, Thomas D Butler, Thean Chew, Michael Colwill, Rachel Cooney, Gabriele De Marco, Said Din, Shah
    Gut.2025; 74(Suppl 2): s1.     CrossRef
  • Evolution of inflammatory bowel disease in Korea: a 60-year perspective on clinical and research development
    Suk-Kyun Yang
    Intestinal Research.2025; 23(3): 233.     CrossRef
  • Improving Medication Adherence Levels in Inflammatory Bowel Disease (IBD) Patients: A Narrative Evidence-Based Review
    Obreniokibo Amiesimaka, Kristina Aluzaite, Rhiannon Braund, Michael Schultz
    Patient Preference and Adherence.2024; Volume 18: 905.     CrossRef
  • Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐TNF therapy: A nationwide population‐based study
    Jeongkuk Seo, Seonok Kim, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Ye‐Jee Kim, Byong Duk Ye
    Alimentary Pharmacology & Therapeutics.2024; 60(3): 389.     CrossRef
  • Researching Interventions to Improve Medication Adherence in Ulcerative Colitis Patients
    Mila Palma Pacheco, Flora Maria Lorenzo Fortes, Raquel Rocha dos Santos, Genoile Oliveira Santana Silva
    Journal of Coloproctology.2021; 41(01): 096.     CrossRef
  • Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
    You Sun Kim
    Journal of the Korean Medical Association.2021; 64(9): 596.     CrossRef
  • Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs
    Axel Dignass, John Waller, Joseph C. Cappelleri, Irene Modesto, Agnes Kisser, Lena Dietz, Marco DiBonaventura, Robert Wood, Melanie May, Berit Libutzki, Danielle Bargo
    Journal of Medical Economics.2020; 23(4): 415.     CrossRef
  • Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
    Alistair Murray, Tran M Nguyen, Claire E Parker, Brian G Feagan, John K MacDonald
    Cochrane Database of Systematic Reviews.2020;[Epub]     CrossRef
  • 12,341 View
  • 198 Download
  • 8 Web of Science
  • 9 Crossref
Close layer
Intest Res : Intestinal Research
© Korean Association for the Study of Intestinal Diseases.
Close layer
TOP